Last reviewed · How we verify
Org 5730 (BEPRIDIL)
Org 5730, also known as Bepridil, is a high-risk QT prolonging agent that was originally developed by Organon and is currently owned by a generic manufacturer. It is a small molecule that targets the voltage-dependent P/Q-type calcium channel subunit alpha-1A. Bepridil was FDA approved in 1990 for the treatment of angina pectoris. It has a half-life of 14.9 hours and bioavailability of 61%. Bepridil is off-patent and has no active Orange Book patents.
At a glance
| Generic name | BEPRIDIL |
|---|---|
| Drug class | High Risk QT Prolonging Agents |
| Target | Voltage-dependent P/Q-type calcium channel subunit alpha-1A |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1990 |
Approved indications
- Angina pectoris
Common side effects
Drug interactions
- High Risk QT Prolonging Agents
- bumetanide
- erythromycin
- fosamprenavir
- furosemide
- hydrochlorothiazide
- ritonavir
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Measurement of Heart-carotid Pulse Wave Velocity (hcPWV) by Laser Doppler Vibrometry (LDV) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Org 5730 CI brief — competitive landscape report
- Org 5730 updates RSS · CI watch RSS